Amid the end of a national GLP-1 shortage, the FDA will now require all compounding, distributing, or dispensing of compounded tirzepatide injections to end within 90 days.

Collaboration aims to enhance PSMA-B ligand, a novel theranostic molecule in development for the treatment of prostate cancer.

In this part of his Pharmaceutical Executive video interview, Peter Ax, CEO of UpScriptHealth, discusses the role of telehealth he envisions when it comes to expanding access to care for patients with complex or rare diseases.

The latest news for pharma industry insiders.

Sermo’s survey also reveals some troubling aspects about the public’s relationship with these medications.

The Upscript Health CEO discusses trends in telehealth for the coming year.

The molecule is an investigational pre-clinical oral GLP-1 receptor agonist.

Breakthrough Therapy designation for Trodelvy was granted based on promising results from the Phase II TROPiCS-03 study, which showed encouraging antitumor activity in both platinum-resistant and platinum-sensitive extensive-stage small cell lung cancer.

Approval of Steqeyma was based on a comprehensive evidence review, including a Phase III trial in moderate to severe plaque psoriasis.

New biologics license applications seek FDA approval for Merck’s clesrovimab to protect infants and children from respiratory syncytial virus and Johnson & Johnson’s Simponi for the treatment of ulcerative colitis.

PharmaLex’s chief strategy officer discusses strategies to improve monetization for these drugs.

The latest news for pharma industry insiders.

Margaret Keegan, the new CEO of Precision Medicine Group, is eager to elevate the profile of the expert-rich service provider and build it into an industry leader in next-gen drug development and commercialization support.

The biosimilars market in the US is on the rise, but barriers to greater adoption remain.

Approval of Vtama for atopic dermatitis provides a steroid-free treatment option for adults and pediatric patients.

Unleashed demand over the past year characterizes the M&A picture in pharma.

The latest news for pharma industry insiders.

In this part of her Pharmaceutical Executive video interview, Angela Tenuta, President, Full Service Agencies, at EVERSANA INTOUCH, shares some best practices for pharma companies to ensure their messaging resonates across different cultures and healthcare systems.

Regulatory, technological, and other factors are set to have a significant impact in the coming year.

This will bring Nimble’s psoriasis and inflammatory bowel disease treatment under AbbVie’s pipeline.

The Breakthrough Therapy Designation for Jemperli was based on Phase II clinical trial data, showing a 100% clinical complete response rate in patients with locally advanced mismatch repair deficient/microsatellite instability-high rectal cancer.

With the Inflation Reduction Act now in flux, how will the government and industry respond?

How alternative direct-to-consumer models are changing the landscape for patient access.

Approval of Unloxcyt was based on results from the CK-301-101 trial, which showed the drug is the first FDA-approved PD-L1–blocking antibody to produce clinically meaningful and durable objective response rates in patients with metastatic or locally advanced cutaneous squamous cell carcinoma.

The swell of AI-powered digital platforms puts future decision-making under the spotlight.